Nospharma announces a new strategic partnership with the the FRAXA Research Foundation to conduct pre-clinical testing of NOS-01, a potential new treatment for Fragile X Syndrome. This partnership ...
Researchers have developed an innovative new nanopore sequencing assay to identify carriers of fragile X syndrome (FXS), the leading cause of monogenic autism spectrum disorder and inherited ...
Scientists have created a new therapeutic approach for testing fragile X syndrome, which is the most common genetic cause of autism spectrum disorder (ASD). This method aims to alter a type of neural ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results